Trending - Altmetric
- Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaLast mentioned on Mon Sep 13 2021
- Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T Cell TherapyLast mentioned on Fri Sep 17 2021
- How to provide the needed protection from COVID-19 to patients with hematologic malignanciesLast mentioned on Sun Sep 19 2021
- Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignanciesLast mentioned on Fri Sep 17 2021
- Bispecific Antibodies in Multiple Myeloma: Present and FutureLast mentioned on Fri Sep 17 2021
- Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid LeukemiaLast mentioned on Sat Aug 28 2021
- Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1Last mentioned on Sun Sep 12 2021
- Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple MyelomaLast mentioned on Fri Aug 27 2021
- Scalable Manufacturing of CAR T Cells for Cancer ImmunotherapyLast mentioned on Tue Sep 14 2021
- Checkpoint Blockade + Chemotherapy: the Right Combination for AML?Last mentioned on Mon Sep 13 2021
- Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic TherapyLast mentioned on Wed Sep 01 2021
- Mutation Signatures of Pediatric Acute Myeloid Leukemia and Normal Blood Progenitors Associated with Differential Patient OutcomesLast mentioned on Fri Sep 17 2021
- Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple MyelomaLast mentioned on Wed Aug 25 2021
- Integrative Genomic Analysis of Pediatric Myeloid Related Acute Leukemias Identifies Novel Subtypes and Prognostic IndicatorsLast mentioned on Thu Sep 09 2021
- Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in HealthcareLast mentioned on Sat Sep 11 2021
- Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid LeukemiaLast mentioned on Wed Sep 15 2021
- Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19Last mentioned on Fri Aug 27 2021
- Overcoming Acquired Epigenetic Resistance to BTK InhibitorsLast mentioned on Sat Sep 18 2021
- ZBTB33 Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA SplicingLast mentioned on Tue Sep 14 2021
- A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase InhibitorsLast mentioned on Fri Sep 17 2021
- Hyperthermia Selectively Destabilizes Oncogenic Fusion ProteinsLast mentioned on Thu Aug 26 2021
- Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway ActivationLast mentioned on Tue Sep 07 2021
- ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentLast mentioned on Fri Aug 27 2021
Pages